Abstract
Background We collected hospitalization, death, and vaccination status data for all 111,052 laboratory-confirmed SARS-CoV-2 infections in Puerto Rico since the first COVID-19 vaccine was administered starting on December 15, 2020 and ending October 1, 2021. Using these data we estimated real-world time-varying effectiveness of the mRNA-1273 (Moderna), BNT162b2 (Pfizer), and Ad26.COV2.S (J & J) COVID-19 vaccines to quantify the public health benefits of Puerto Rico’s immunization campaign. Furthermore, we compared the effectiveness of the COVID-19 vaccines before and after the dominance of the Delta variant. As of this writing, Puerto Rico had a higher vaccination rate and lower SARS-CoV-2 infection rate than all 50 States in the USA.
Methods We used data obtained from the integration of the Puerto Rico Department of Health databases holding vaccination status, SARS-CoV-2 test results, and COVID-19 hospitalizations, and deaths. We estimated time-varying vaccine effectiveness against SARS-CoV-2 infections by fitting a statistical model that adjusts for time-varying incidence rates, age, gender, and day of the week. We also used this model to estimate the relative risk of hospitalization and deaths comparing vaccinated to unvaccinated individuals. Code and data are provided to reproduce the analysis here: https://github.com/rafalab/vax-eff-pr.
Results All vaccines were effective at reducing risks for all outcomes across all age groups. At the peak of their protection, mRNA-1273, BNT162b2, and Ad26.COV2.S had an effectiveness of 90% (88% - 91%), 87% (85% - 89%), and 58% (51% - 65%). After four months, effectiveness waned to about 70%, 60%, and 30% for mRNA-1273, BNT162b2, and Ad26.COV2.S, respectively. All vaccines had a lower effectiveness for those over 85 years, with the decrease in effectiveness particularly low for the Ad26.COV2.S vaccine. We found no clear evidence that effectiveness was different after the Delta variant became dominant. For those infected, the vaccines provided further protection against hospitalization and deaths across all age groups, although the protection was less for those above 85 years. Using the rates observed for the unvaccinated we would have observed 6,273 and 2,096 hospitalizations and deaths among the vaccinated population but we instead observed 744 and 167, respectively.
Conclusions The mRNA-1273 and BNT162b2 vaccines where highly effective across all age groups. They were still effective after four months although the protection did wain. The Ad26.COV2.S vaccine was effective but to a lesser degree, especially for the older age groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
R35GM131802
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The code and data needed to reproduce the analysis is made publicly available here: https://github.com/rafalab/vax-eff-pr
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The code and data needed to reproduce the analysis is made publicly available here: https://github.com/rafalab/vax-eff-pr
